Abstract:Abstract Introduction: Tertiary lymphoid structure (TLS) has been found to associate with good prognosis in various cancer types including esophageal squamous cell carcinoma (ESCC). A recent study involving patients receiving curative surgical resection alone for localized ESCC showed TLS as a favorable prognostic factor associated with improved progression free survival (Hayashi et al. British Journal of Cancer, 2023;128:2175-2185). Our study aimed to investigate the prognostic significance of TLS in patients with locally advanced ESCC receiving neoadjuvant chemoradiotherapy (CRT). Patients and Methods: We retrospectively enrolled 137 patients of locally advanced ESCC patients from two referral centers of Taiwan from 2002 to 2018. All patients received paclitaxel/platinum-based CRT followed by esophagectomy. Primary esophageal tumor tissues biopsied endoscopically before treatment were collected for immunohistochemical stains for CD20 (clone L26; Zytomed, Berlin, Germany) and CD23 (clone DAK-CD23; agilent Dako, California, U.S.A.). The TLS status of each patient was defined as no TLS (no aggregation of CD20-positive cells), immature TLS (aggregation of CD20-positive cells without CD23-positive cells in it), and mature TLS (aggregation of CD20-positive cells with CD23-positive cells in it). The associations of the TLS status with pathologic complete response (pCR) and overall survival (OS) were analyzed univariately and multivariately by logistic regression and cox regression, respectively. The variables included in the analyses were age, gender, tumor location, clinical T stage, clinical N stage, the institutes, PD-L1 expression on tumor cells (PD-L1 TC) and immune cells (PD-L1 IC), and the TLS status. Results: The median age was 54 years with 125 males and 12 females. The TLS status of no, immature, and mature TLS were seen in 64, 40, and 33 patients, respectively. Mature TLS was associated with PD-L1 IC (p=0.0007). Compared to no TLS, mature TLS associated with lower pCR rate (24% vs 47%) in both univariate (OR: 0.36, p=0.034) and multivariate (OR: 0.26, p=0.023) analysis. Compared to no TLS, mature TLS was associated with shorter OS (median OS: 27 vs 46 months) in multivariate analysis (HR: 2.96, p=0.0008), but not in univariate analysis (HR: 1.29, p=0.29). Other prognostic factors associated with OS in multivariate analysis include male gender (HR: 2.88, p=0.021), PD-L1 TC (HR: 1.62, p=0.039), and PD-L1 IC (HR: 0.30, p<0.0001). Conclusion: Mature TLS is an independent factor for poor treatment outcomes, including pathologic response and overall survival in locally advanced ESCC patients receiving neoadjuvant CRT. Additional studies are warranted to validate this finding. (The study was supported by the grant NTUH 110-S5021, MOST 108-2314-B-002-076-MY3, and MOHW 111-TDU-B-221-114006) Citation Format: Ta-Chen Huang, Cher-Wei Liang, Yu-I Li, Jhe-Cyuan Guo, Chia-Chi Lin, Jang-Ming Lee, Yin-Kai Chao, Chih-Hung Hsu. Tertiary lymphoid structure associates with poor prognosis in locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 7654.

Prognostic Value of the International Association for the Study of Lung Cancer Grading System and its Association with the Tumor Microenvironment in Stage I EGFR-muted Lung Adenocarcinoma

Preoperative Prognostic Prediction for Stage I Lung Adenocarcinomas: Impact of the Computed Tomography Features Associated with the New Histological Grading System

Prognostic impact of pattern-based grading system by the new IASLC/ATS/ERS classification in Asian patients with stage I lung adenocarcinoma

P2.01-057 Association of Tumor Infiltrating Lymphocytes Quantification with EGFR Mutations in Completely Resected Stage IIIA(N2) Lung Adenocarcinoma: Topic: Immune Mechanisms in Thoracic Cancer and Targeted Therapy

[Prognostic Significance of a Newly Proposed Grading and Scoring System in Stage I Pulmonary Adenocarcinoma].

Grading of Endocervical Adenocarcinoma: a Novel Prognostic System Based on Tumor Budding and Cell Cluster Size.

Abstract 7654: Tertiary Lymphoid Structure Associates with Poor Prognosis in Locally Advanced Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy

Validation Study of New IASLC Histology Grading System in Stage I Non-Mucinous Adenocarcinoma Comparing With Minimally Invasive Adenocarcinoma

Prognostic Value of Tumor Immune Microenvironment Factors in Patients with Stage I Lung Adenocarcinoma.

Proposed novel grading system for stage I invasive lung adenocarcinoma and a comparison with the 2020 IASLC grading system

[Prognostic Significance and Grading of Stromal Invasion in Pt1 Adenocarcinoma of Lung].

Significant difference in recurrence according to the proportion of high grade patterns in stage IA lung adenocarcinoma

Validation of the Novel International Association for the Study of Lung Cancer Grading System for Invasive Pulmonary Adenocarcinoma and Association with Common Driver Mutations.

Prognostic impact of the IASLC grading system of lung adenocarcinoma: a systematic review and meta‐analysis

The role of extensive lymph node dissection in the new grading system for lung adenocarcinoma

The Grading System for Lung Adenocarcinoma: Brief Review of its Prognostic Performance and Future Directions

Tumor stroma ratio, tumor stroma maturity, tumor-infiltrating immune cells in relation to prognosis, and neoadjuvant therapy response in esophagogastric junction adenocarcinoma

A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee

Prognostic significance of tumor microenvironment assessed by machine learning algorithm in surgically resected non-small cell lung cancer

Correlation of Survival and EGFR Mutation with Predominant Histologic Subtype According to the New Lung Adenocarcinoma Classification in Stage IB Patients

Histopathologic Pattern and Molecular Risk Stratification Are Associated with Prognosis in Patients with Stage IB Lung Adenocarcinoma